Burning Rock Biotech (NASDAQ:BNR) (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.
Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities. The company went public on the NASDAQ stock exchange in December 2015, opening access to international capital markets and enhancing its visibility in the global precision medicine arena. Over the years, Burning Rock Biotech has invested in upgrading its sequencing platforms and bioinformatics pipelines to broaden its test menu and improve turnaround times.
Burning Rock Biotech offers an array of companion diagnostics and comprehensive genomic profiling assays that cover key oncogenes and tumor suppressor genes implicated in lung, colorectal, breast and other cancers. Its products include blood-based NGS panels for single-gene and multi-gene mutation detection, as well as tumor tissue assays for patients undergoing invasive biopsy procedures. The company also collaborates with pharmaceutical partners to develop targeted therapy trials, providing companion diagnostic support for drug development programs and regulatory submissions.
The company is led by a management team composed of scientists and industry veterans with extensive experience in molecular diagnostics, oncology research and clinical laboratory operations. Under its leadership, Burning Rock Biotech continues to pursue strategic partnerships and technology enhancements, with the goal of extending its reach beyond China and into broader Asia-Pacific markets. As precision oncology evolves, the company remains focused on delivering high-quality, scalable testing solutions that support more informed treatment decisions for cancer patients worldwide.
